$BGNE with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $BGNE after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.24 USD
−881.71 M USD
2.46 B USD
96.17 M
About BEIGENE, LTD.
Sector
CEO
John V. Oyler
Headquarters
George Town
Website
Founded
2010
FIGI
BBG00B6WF7T5
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 80%.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 100%.
#6160 pull-back and hits support line $213.6 Hi Everybody
#6160 pull-back and hits support line $213.6, expects to test the BLUE LINES, and stops if closes below the RED line.
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA BGNE: BeiGene, Ltd.
2021-07-29 20:00:00
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
BGNE short above 260$, target price 161$, about Mar 9, 2021.BGNE short above 260$, target price 161$, about Mar 9, 2021.
Similar pattern of Aug 8, 2018.
Wait BGNE price reached 161$, start building long position.
It's not a good idea holding BGNE under 270$~260$
Long stop-Loss price : 259$
Short stop-loss price : 284$
BGNE: Long strategy after gap overlapWe will trade long in the range $140 - 150 amid to gap overlap. Target will be $190 / 200. (+30% potentially)
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where BGNE is featured.
